Racial and ethnic differences in the pathogenesis and clinical manifestations of uterine leiomyoma

Seminars in Reproductive Medicine

Volumn 31, Issue 5, 2013, Pages 370-379

  Catherino, Williamh ^a,b   Eltoukhi, Hebam ^a,c   Al Hendy, Ayman ^d  

^a EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

^b UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES   (United States)

^c Suez Canal University Faculty of Medicine   (Egypt)

^d MEHARRY MEDICAL COLLEGE   (United States)

Author keywords

African American; ethnicity; molecular; risk factor; uterine leiomyoma

Indexed keywords

CATECHOL METHYLTRANSFERASE; CELL NUCLEUS RECEPTOR; CYTOCHROME P450 17; CYTOCHROME P450 1A1; ESTROGEN RECEPTOR; LIAROZOLE; MICRORNA; PROGESTERONE RECEPTOR; RETINOIC ACID; RETINOID X RECEPTOR ALPHA; TRANSFORMING GROWTH FACTOR BETA; VITAMIN D;

AFRICAN AMERICAN; ARTICLE; CELL PROLIFERATION; CULTURAL FACTOR; DNA POLYMORPHISM; ECHOGRAPHY; ENVIRONMENTAL FACTOR; ESTROGEN SYNTHESIS; ETHNIC DIFFERENCE; GENE EXPRESSION; HUMAN; HYSTERECTOMY; LEYDIG CELL; MICROARRAY ANALYSIS; MOLECULAR MECHANICS; MYOMECTOMY; ONSET AGE; RACE DIFFERENCE; RISK FACTOR; UTERUS MYOMA; VITAMIN D DEFICIENCY;

AFRICAN AMERICANS; ANIMALS; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HEALTH STATUS DISPARITIES; HUMANS; LEIOMYOMA; LEIOMYOMATOSIS; UNITED STATES; UTERINE NEOPLASMS;

EID: 84881531955     PISSN: 15268004     EISSN: 15264564     Source Type: Journal    
DOI: 10.1055/s-0033-1348896     Document Type: Article

References (128)

1. Baird D. D., Dunson D. B., Hill M. C., Cousins D., Schectman J. M. High cumulative incidence of uterine leiomyoma in black and white women: ultrasound evidence. Am J Obstet Gynecol: 2003; 188 1 100 107 (Pubitemid 36135604)
2. Marshall L. M., Spiegelman D., Barbieri R. L., et al. Variation in the incidence of uterine leiomyoma among premenopausal women by age and race. Obstet Gynecol: 1997; 90 6 967 973 (Pubitemid 27510139)
3. Kjerulff K. H., Langenberg P., Seidman J. D., Stolley P. D., Guzinski G. M. Uterine leiomyomas. Racial differences in severity, symptoms and age at diagnosis. J Reprod Med: 1996; 41 7 483 490 (Pubitemid 26244348)
4. Cardozo E. R., Clark A. D., Banks N. K., Henne M. B., Stegmann B. J., Segars J. H. The estimated annual cost of uterine leiomyomata in the United States. Am J Obstet Gynecol: 2012; 206 3 e1 e9
5. Shynlova O., Tsui P., Jaffer S., Lye S. J. Integration of endocrine and mechanical signals in the regulation of myometrial functions during pregnancy and labour. Eur J Obstet Gynecol Reprod Biol: 2009; 144 01 S2 S10
6. Walker C. L., Stewart E. A. Uterine fibroids: the elephant in the room. Science: 2005; 308 5728 1589 1592 (Pubitemid 40807499)
7. Andersen J., Barbieri R. L. Abnormal gene expression in uterine leiomyomas. J Soc Gynecol Investig: 1995; 2 5 663 672
8. Wallach E. E., Vlahos N. F. Uterine myomas: an overview of development, clinical features, and management. Obstet Gynecol: 2004; 104 2 393 406 (Pubitemid 40458890)
9. Chegini N. Proinflammatory and profibrotic mediators: principal effectors of leiomyoma development as a fibrotic disorder. Semin Reprod Med: 2010; 28 3 180 203
10. Catherino W. H., Leppert P. C., Stenmark M. H., et al. Reduced dermatopontin expression is a molecular link between uterine leiomyomas and keloids. Genes Chromosomes Cancer: 2004; 40 3 204 217 (Pubitemid 38703097)
11. Leppert P. C., Baginski T., Prupas C., Catherino W. H., Pletcher S., Segars J. H. Comparative ultrastructure of collagen fibrils in uterine leiomyomas and normal myometrium. Fertil Steril: 2004; 82 03 1182 1187 (Pubitemid 39335936)
12. Dimitrova I. K., Richer J. K., Rudolph M. C., et al. Gene expression profiling of multiple leiomyomata uteri and matched normal tissue from a single patient. Fertil Steril: 2009; 91 6 2650 2663
13. Wei T., Geiser A. G., Qian H. R., et al. DNA microarray data integration by ortholog gene analysis reveals potential molecular mechanisms of estrogen-dependent growth of human uterine fibroids. BMC Womens Health: 2007; 7 5
14. Wei J. J., Chiriboga L., Arslan A. A., Melamed J., Yee H., Mittal K. Ethnic differences in expression of the dysregulated proteins in uterine leiomyomata. Hum Reprod: 2006; 21 1 57 67 (Pubitemid 41794292)
15. Wei J. J., Chiriboga L., Mittal K. Expression profile of the tumorigenic factors associated with tumor size and sex steroid hormone status in uterine leiomyomata. Fertil Steril: 2005; 84 2 474 484 (Pubitemid 41125273)
16. Ahn W. S., Kim K. W., Bae S. M., et al. Targeted cellular process profiling approach for uterine leiomyoma using cDNA microarray, proteomics and gene ontology analysis. Int J Exp Pathol: 2003; 84 6 267 279 (Pubitemid 38221805)
17. Wang H., Mahadevappa M., Yamamoto K., et al. Distinctive proliferative phase differences in gene expression in human myometrium and leiomyomata. Fertil Steril: 2003; 80 2 266 276 (Pubitemid 36959779)
18. Malik M., Norian J., McCarthy-Keith D., Britten J., Catherino W. H. Why leiomyomas are called fibroids: the central role of extracellular matrix in symptomatic women. Semin Reprod Med: 2010; 28 3 169 179
19. Zaitseva M., Vollenhoven B. J., Rogers P. A. In vitro culture significantly alters gene expression profiles and reduces differences between myometrial and fibroid smooth muscle cells. Mol Hum Reprod: 2006; 12 3 187 207
20. Pan Q., Luo X., Chegini N. Genomic and proteomic profiling I: leiomyomas in African Americans and Caucasians. Reprod Biol Endocrinol: 2007; 5 34
21. Al-Hendy A., Salama S. A. Ethnic distribution of estrogen receptor-alpha polymorphism is associated with a higher prevalence of uterine leiomyomas in black Americans. Fertil Steril: 2006; 86 3 686 693 (Pubitemid 44307032)
22. Djuranovic S., Nahvi A., Green R. A parsimonious model for gene regulation by miRNAs. Science: 2011; 331 6017 550 553
23. Morikawa J., Yoshida S., Kennedy S., et al. Association study between catechol-O-methyltransferase polymorphisms and uterine leiomyomas in a Japanese population. Clin Exp Obstet Gynecol: 2008; 35 1 35 40 (Pubitemid 351345814)
24. Denschlag D., Bentz E. K., Hefler L., et al. Genotype distribution of estrogen receptor-alpha, catechol-O-methyltransferase, and cytochrome P450 17 gene polymorphisms in Caucasian women with uterine leiomyomas. Fertil Steril: 2006; 85 2 462 467 (Pubitemid 43170924)
25. Al-Hendy A., Salama S. A. Catechol-O-methyltransferase polymorphism is associated with increased uterine leiomyoma risk in different ethnic groups. J Soc Gynecol Investig: 2006; 13 2 136 144 (Pubitemid 43155847)
26. Gooden K. M., Schroeder J. C., North K. E., et al. Val153Met polymorphism of catechol-O-methyltransferase and prevalence of uterine leiomyomata. Reprod Sci: 2007; 14 2 117 120 (Pubitemid 351168836)
27. de Oliveira E., de Aquino Castro R., Gomes M. T., et al. The catechol-O-methyltransferase (COMT) gene polymorphism and prevalence of uterine fibroids. Maturitas: 2008; 60 3-4 235 238
28. Salama S. A., Ho S. L., Wang H. Q., Tenhunen J., Tilgmann C., Al-Hendy A. Hormonal regulation of catechol-O-methyl transferase activity in women with uterine leiomyomas. Fertil Steril: 2006; 86 1 259 262 (Pubitemid 43977765)
29. Ates O., Demirturk F., Toprak M., Sezer S. Polymorphism of catechol-O-methyltransferase and uterine leiomyoma. Mol Cell Biochem: 2013; 375 1-2 179 183
30. Chuang T. D., Panda H., Luo X., Chegini N. miR-200c is aberrantly expressed in leiomyomas in an ethnic-dependent manner and targets ZEBs, VEGFA, TIMP2, and FBLN5. Endocr Relat Cancer: 2012; 19 4 541 556
31. Wang T., Zhang X., Obijuru L., et al. A micro-RNA signature associated with race, tumor size, and target gene activity in human uterine leiomyomas. Genes Chromosomes Cancer: 2007; 46 4 336 347 (Pubitemid 46411325)
32. Lachman H. M., Papolos D. F., Saito T., Yu Y. M., Szumlanski C. L., Weinshilboum R. M. Human catechol-O-methyltransferase pharmacogenetics: description of a functional polymorphism and its potential application to neuropsychiatric disorders. Pharmacogenetics: 1996; 6 3 243 250 (Pubitemid 26226317)
33. Hassan M. H., Fouad H., Bahashwan S., Al-Hendy A. Towards non-surgical therapy for uterine fibroids: catechol-O-methyl transferase inhibitor shrinks uterine fibroid lesions in the Eker rat model. Hum Reprod: 2011; 26 11 3008 3018
34. Carey A. H., Waterworth D., Patel K., et al. Polycystic ovaries and premature male pattern baldness are associated with one allele of the steroid metabolism gene CYP17. Hum Mol Genet: 1994; 3 10 1873 1876 (Pubitemid 24310487)
35. Picado-Leonard J., Miller W. L. Cloning and sequence of the human gene for P450c17 (steroid 17 alpha-hydroxylase/17,20 lyase): similarity with the gene for P450c21. DNA: 1987; 6 5 439 448 (Pubitemid 18085844)
36. Amant F., Dorfling C. M., de Brabanter J., et al. A possible role of the cytochrome P450c17alpha gene (CYP17) polymorphism in the pathobiology of uterine leiomyomas from black South African women: a pilot study. Acta Obstet Gynecol Scand: 2004; 83 3 234 239 (Pubitemid 38338861)
37. Pakiz M., Potocnik U., But I., Mujezinovic F. A CYP17A1 gene polymorphism in association with multiple uterine leiomyomas: a meta-analysis. Cancer Biomark 2010-: 2011; 8 1 29 34
38. Taioli E., Trachman J., Chen X., Toniolo P., Garte S. J. A CYP1A1 restriction fragment length polymorphism is associated with breast cancer in African-American women. Cancer Res: 1995; 55 17 3757 3758
39. El-Shennawy G. A., Elbialy A. A., Isamil A. E., El Behery M. M. Is genetic polymorphism of ER-α, CYP1A1, and CYP1B1 a risk factor for uterine leiomyoma? Arch Gynecol Obstet: 2011; 283 6 1313 1318
40. Ye Y., Cheng X., Luo H. B., Liu L., Li Y. B., Hou Y. P. CYP1A1 and CYP1B1 genetic polymorphisms and uterine leiomyoma risk in Chinese women. J Assist Reprod Genet: 2008; 25 8 389 394
41. Herr D., Bettendorf H., Denschlag D., Keck C., Pietrowski D. Cytochrome P2A13 and P1A1 gene polymorphisms are associated with the occurrence of uterine leiomyoma. Arch Gynecol Obstet: 2006; 274 6 367 371 (Pubitemid 44440535)
42. Willis B. C., Borok Z. TGF-beta-induced EMT: mechanisms and implications for fibrotic lung disease. Am J Physiol Lung Cell Mol Physiol: 2007; 293 3 L525 L534 (Pubitemid 47358808)
43. Liu Y. Renal fibrosis: new insights into the pathogenesis and therapeutics. Kidney Int: 2006; 69 2 213 217 (Pubitemid 43323069)
44. Yata Y., Gotwals P., Koteliansky V., Rockey D. C. Dose-dependent inhibition of hepatic fibrosis in mice by a TGF-beta soluble receptor: implications for antifibrotic therapy. Hepatology: 2002; 35 5 1022 1030 (Pubitemid 34453999)
45. Verrecchia F., Mauviel A., Farge D. Transforming growth factor-beta signaling through the Smad proteins: role in systemic sclerosis. Autoimmun Rev: 2006; 5 8 563 569 (Pubitemid 44488757)
46. Bonniaud P., Margetts P. J., Ask K., Flanders K., Gauldie J., Kolb M. TGF-beta and Smad3 signaling link inflammation to chronic fibrogenesis. J Immunol: 2005; 175 8 5390 5395 (Pubitemid 41456425)
47. Carrino D. A., Mesiano S., Barker N. M., Hurd W. W., Caplan A. I. Proteoglycans of uterine fibroids and keloid scars: similarity in their proteoglycan composition. Biochem J: 2012; 443 2 361 368
48. Sinclair D. C., Mastroyannis A., Taylor H. S. Leiomyoma simultaneously impair endometrial BMP-2-mediated decidualization and anticoagulant expression through secretion of TGF-β3. J Clin Endocrinol Metab: 2011; 96 2 412 421
49. Ding L., Xu J., Luo X., Chegini N. Gonadotropin releasing hormone and transforming growth factor beta activate mitogen-activated protein kinase/extracellularly regulated kinase and differentially regulate fibronectin, type I collagen, and plasminogen activator inhibitor-1 expression in leiomyoma and myometrial smooth muscle cells. J Clin Endocrinol Metab: 2004; 89 11 5549 5557 (Pubitemid 39518439)
50. Lee B. S., Nowak R. A. Human leiomyoma smooth muscle cells show increased expression of transforming growth factor-beta 3 (TGF beta 3) and altered responses to the antiproliferative effects of TGF beta. J Clin Endocrinol Metab: 2001; 86 2 913 920 (Pubitemid 32207515)
51. Eiser A. R. Does over-expression of transforming growth factor-beta account for the increased morbidity in African-Americans? Possible clinical study and therapeutic implications. Med Hypotheses: 2010; 75 5 418 421
52. Arici A., Sozen I. Transforming growth factor-beta3 is expressed at high levels in leiomyoma where it stimulates fibronectin expression and cell proliferation. Fertil Steril: 2000; 73 5 1006 1011 (Pubitemid 30227527)
53. Derynck R., Lindquist P. B., Lee A., et al. A new type of transforming growth factor-beta, TGF-beta 3. EMBO J: 1988; 7 12 3737 3743
54. Norian J. M., Malik M., Parker C. Y., et al. Transforming growth factor beta3 regulates the versican variants in the extracellular matrix-rich uterine leiomyomas. Reprod Sci: 2009; 16 12 1153 1164
55. Joseph D. S., Malik M., Nurudeen S., Catherino W. H. Myometrial cells undergo fibrotic transformation under the influence of transforming growth factor beta-3. Fertil Steril: 2010; 93 5 1500 1508
56. Xu J., Luo X., Chegini N. Differential expression, regulation, and induction of Smads, transforming growth factor-beta signal transduction pathway in leiomyoma, and myometrial smooth muscle cells and alteration by gonadotropin-releasing hormone analog. J Clin Endocrinol Metab: 2003; 88 3 1350 1361 (Pubitemid 36337800)
57. Zhang D., Al-Hendy M., Richard-Davis G., Montgomery-Rice V., Rajaratnam V., Al-Hendy A. Antiproliferative and proapoptotic effects of epigallocatechin gallate on human leiomyoma cells. Fertil Steril: 2010; 94 5 1887 1893
58. Halder S. K., Goodwin J. S., Al-Hendy A. 1,25-Dihydroxyvitamin D3 reduces TGF-beta3-induced fibrosis-related gene expression in human uterine leiomyoma cells. J Clin Endocrinol Metab: 2011; 96 4 E754 E762
59. Di X., Andrews D. M., Tucker C. J., et al. A high concentration of genistein down-regulates activin A, Smad3 and other TGF-β pathway genes in human uterine leiomyoma cells. Exp Mol Med: 2012; 44 4 281 292
60. Grudzien M. M., Low P. S., Manning P. C., Arredondo M., Belton R. J. Jr, Nowak R. A. The antifibrotic drug halofuginone inhibits proliferation and collagen production by human leiomyoma and myometrial smooth muscle cells. Fertil Steril: 2010; 93 4 1290 1298
61. Zhang C. H., Wen Z. Q., Li J. F., et al. Inhibition of proliferation and transforming growth factor beta3 protein expression by peroxisome proliferators-activated receptor gamma ligands in human uterine leiomyoma cells. Chin Med J (Engl): 2008; 121 2 166 171
62. Wang J., Ohara N., Wang Z., et al. A novel selective progesterone receptor modulator asoprisnil (J867) down-regulates the expression of EGF, IGF-I, TGFbeta3 and their receptors in cultured uterine leiomyoma cells. Hum Reprod: 2006; 21 7 1869 1877 (Pubitemid 44028263)
63. Bajracharya P., Lee E. J., Lee D. M., et al. Effect of different ingredients in traditional Korean medicine for human uterine leiomyoma on normal myometrial and leiomyomal smooth muscle cell proliferation. Arch Pharm Res: 2009; 32 11 1555 1563
64. Malik M., Catherino W. H. Development and validation of a three-dimensional in vitro model for uterine leiomyoma and patient-matched myometrium. Fertil Steril: 2012; 97 6 1287 1293
65. Catherino W. H., Malik M. Uterine leiomyomas express a molecular pattern that lowers retinoic acid exposure. Fertil Steril: 2007; 87 6 1388 1398 (Pubitemid 46829156)
66. Boettger-Tong H., Shipley G., Hsu C. J., Stancel G. M. Cultured human uterine smooth muscle cells are retinoid responsive. Proc Soc Exp Biol Med: 1997; 215 1 59 65
67. Tsibris J. C., Porter K. B., Jazayeri A., et al. Human uterine leiomyomata express higher levels of peroxisome proliferator-activated receptor gamma, retinoid X receptor alpha, and all-trans retinoic acid than myometrium. Cancer Res: 1999; 59 22 5737 5744
68. Malik M., Webb J., Catherino W. H. Retinoic acid treatment of human leiomyoma cells transformed the cell phenotype to one strongly resembling myometrial cells. Clin Endocrinol (Oxf): 2008; 69 3 462 470
69. Huang M. E., Ye Y. C., Chen S. R., et al. Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia. Blood: 1988; 72 2 567 572
70. Lippman S. M., Parkinson D. R., Itri L. M., et al. 13-cis-retinoic acid and interferon alpha-2a: effective combination therapy for advanced squamous cell carcinoma of the skin. J Natl Cancer Inst: 1992; 84 4 235 241
71. Kessler J. F., Meyskens F. L. Jr, Levine N., Lynch P. J., Jones S. E. Treatment of cutaneous T-cell lymphoma (mycosis fungoides) with 13-cis-retinoic acid. Lancet: 1983; 1 8338 1345 1347 (Pubitemid 13100195)
72. Toma S., Bonelli L., Sartoris A., et al. 13-cis retinoic acid in head and neck cancer chemoprevention: results of a randomized trial from the Italian Head and Neck Chemoprevention Study Group. Oncol Rep: 2004; 11 6 1297 1305
73. Gamage S. D., Bischoff E. D., Burroughs K. D., et al. Efficacy of LGD1069 (Targretin), a retinoid X receptor-selective ligand, for treatment of uterine leiomyoma. J Pharmacol Exp Ther: 2000; 295 2 677 681
74. De Coster R., Wouters W., Van Ginckel R., et al. Experimental studies with liarozole (R 75,251): an antitumoral agent which inhibits retinoic acid breakdown. J Steroid Biochem Mol Biol: 1992; 43 1-3 197 201
75. Bhushan M., Burden A. D., McElhone K., James R., Vanhoutte F. P., Griffiths C. E. Oral liarozole in the treatment of palmoplantar pustular psoriasis: a randomized, double-blind, placebo-controlled study. Br J Dermatol: 2001; 145 4 546 553
76. Gilden M., Malik M., Britten J., Delgado T., Levy G., Catherino W. H. Leiomyoma fibrosis inhibited by liarozole, a retinoic acid metabolic blocking agent. Fertil Steril: 2012; 98 6 1557 1562
77. Bulun S. E., Lin Z., Imir G., et al. Regulation of aromatase expression in estrogen-responsive breast and uterine disease: from bench to treatment. Pharmacol Rev: 2005; 57 3 359 383 (Pubitemid 41196955)
78. Simpson E. R., Clyne C., Rubin G., et al. Aromatase-a brief overview. Annu Rev Physiol: 2002; 64 93 127
79. Folkerd E. J., Newton C. J., Davidson K., Anderson M. C., James V. H. Aromatase activity in uterine leiomyomata. J Steroid Biochem: 1984; 20 5 1195 1200 (Pubitemid 14108622)
80. Pasqualini J. R., Cornier E., Grenier J., Vella C., Schatz B., Netter A. Effect of Decapeptyl, an agonistic analog of gonadotropin-releasing hormone on estrogens, estrogen sulfates, and progesterone receptors in leiomyoma and myometrium. Fertil Steril: 1990; 53 6 1012 1017 (Pubitemid 20208965)
81. Sumitani H., Shozu M., Segawa T., et al. In situ estrogen synthesized by aromatase P450 in uterine leiomyoma cells promotes cell growth probably via an autocrine/intracrine mechanism. Endocrinology: 2000; 141 10 3852 3861
82. Imir A. G., Lin Z., Yin P., et al. Aromatase expression in uterine leiomyomata is regulated primarily by proximal promoters I.3/II. J Clin Endocrinol Metab: 2007; 92 5 1979 1982 (Pubitemid 46997221)
83. Shozu M., Sumitani H., Segawa T., et al. Overexpression of aromatase P450 in leiomyoma tissue is driven primarily through promoter I.4 of the aromatase P450 gene (CYP19). J Clin Endocrinol Metab: 2002; 87 6 2540 2548 (Pubitemid 34655311)
84. Ishikawa H., Reierstad S., Demura M., et al. High aromatase expression in uterine leiomyoma tissues of African-American women. J Clin Endocrinol Metab: 2009; 94 5 1752 1756
85. Norman A. W., Bouillon R. Vitamin D nutritional policy needs a vision for the future. Exp Biol Med (Maywood): 2010; 235 9 1034 1045
86. McDonnell D. P., Mangelsdorf D. J., Pike J. W., Haussler M. R., O'Malley B. W. Molecular cloning of complementary DNA encoding the avian receptor for vitamin D. Science: 1987; 235 4793 1214 1217 (Pubitemid 17034009)
87. Vienonen A., Miettinen S., Bläuer M., et al. Expression of nuclear receptors and cofactors in human endometrium and myometrium. J Soc Gynecol Investig: 2004; 11 2 104 112 (Pubitemid 38229738)
88. Baker A. R., McDonnell D. P., Hughes M., et al. Cloning and expression of full-length cDNA encoding human vitamin D receptor. Proc Natl Acad Sci U S A: 1988; 85 10 3294 3298
89. Wang Q. M., Jones J. B., Studzinski G. P. Cyclin-dependent kinase inhibitor p27 as a mediator of the G1-S phase block induced by 1,25-dihydroxyvitamin D3 in HL60 cells. Cancer Res: 1996; 56 2 264 267 (Pubitemid 26026352)
90. Simboli-Campbell M., Narvaez C. J., van Weelden K., Tenniswood M., Welsh J. Comparative effects of 1,25(OH)2D3 and EB1089 on cell cycle kinetics and apoptosis in MCF-7 breast cancer cells. Breast Cancer Res Treat: 1997; 42 1 31 41 (Pubitemid 27056726)
91. Zhuang S. H., Burnstein K. L. Antiproliferative effect of 1alpha,25-dihydroxyvitamin D3 in human prostate cancer cell line LNCaP involves reduction of cyclin-dependent kinase 2 activity and persistent G1 accumulation. Endocrinology: 1998; 139 3 1197 1207 (Pubitemid 28510139)
92. Colston K. W., Hansen C. M. Mechanisms implicated in the growth regulatory effects of vitamin D in breast cancer. Endocr Relat Cancer: 2002; 9 1 45 59 (Pubitemid 34298363)
93. Sharan C., Halder S. K., Thota C., Jaleel T., Nair S., Al-Hendy A. Vitamin D inhibits proliferation of human uterine leiomyoma cells via catechol-O-methyltransferase. Fertil Steril: 2011; 95 1 247 253
94. Nesby-O'Dell S., Scanlon K. S., Cogswell M. E., et al. Hypovitaminosis D prevalence and determinants among African American and white women of reproductive age: third National Health and Nutrition Examination Survey, 1988-1994. Am J Clin Nutr: 2002; 76 1 187 192 (Pubitemid 34686565)
95. Sabry M., Halder S. K., Allah A. S., Roshdy E., Rajaratnam V., Al-Hendy A. Serum vitamin D3 level inversely correlates with uterine fibroid volume in different ethnic groups: a cross-sectional observational study. Int J Womens Health: 2013; 5 93 100
96. Halder S. K., Sharan C., Al-Hendy A. 1,25-dihydroxyvitamin D3 treatment shrinks uterine leiomyoma tumors in the Eker rat model. Biol Reprod: 2012; 86 4 116
97. Othman E. E., Al-Hendy A. Molecular genetics and racial disparities of uterine leiomyomas. Best Pract Res Clin Obstet Gynaecol: 2008; 22 4 589 601 (Pubitemid 351804123)
98. Jacoby V. L., Fujimoto V. Y., Giudice L. C., Kuppermann M., Washington A. E. Racial and ethnic disparities in benign gynecologic conditions and associated surgeries. Am J Obstet Gynecol: 2010; 202 6 514 521
99. Laughlin S. K., Stewart E. A. Uterine leiomyomas: individualizing the approach to a heterogeneous condition. Obstet Gynecol: 2011; 117 2, Pt 1 396 403
100. Wechter M. E., Stewart E. A., Myers E. R., Kho R. M., Wu J. M. Leiomyoma-related hospitalization and surgery: prevalence and predicted growth based on population trends. Am J Obstet Gynecol: 2011; 205 5 e1 e5
101. Wilcox L. S., Koonin L. M., Pokras R., Strauss L. T., Xia Z., Peterson H. B. Hysterectomy in the United States, 1988-1990. Obstet Gynecol: 1994; 83 4 549 555 (Pubitemid 24221795)
102. Roth T. M., Gustilo-Ashby T., Barber M. D., Myers E. R. Effects of race and clinical factors on short-term outcomes of abdominal myomectomy. Obstet Gynecol: 2003; 101 5, Pt 1 881 884 (Pubitemid 36561248)
103. Abenhaim H. A., Azziz R., Hu J., Bartolucci A., Tulandi T. Socioeconomic and racial predictors of undergoing laparoscopic hysterectomy for selected benign diseases: analysis of 341487 hysterectomies. J Minim Invasive Gynecol: 2008; 15 1 11 15 (Pubitemid 351199829)
104. Baird D. D. Invited commentary: uterine leiomyomata-we know so little but could learn so much. Am J Epidemiol: 2004; 159 2 124 126 (Pubitemid 38082519)
105. Marshall L. M., Spiegelman D., Goldman M. B., et al. A prospective study of reproductive factors and oral contraceptive use in relation to the risk of uterine leiomyomata. Fertil Steril: 1998; 70 3 432 439 (Pubitemid 28435626)
106. Wise L. A., Palmer J. R., Harlow B. L., et al. Reproductive factors, hormonal contraception, and risk of uterine leiomyomata in African-American women: a prospective study. Am J Epidemiol: 2004; 159 2 113 123 (Pubitemid 38082518)
107. Faerstein E., Szklo M., Rosenshein N. Risk factors for uterine leiomyoma: a practice-based case-control study. I. African-American heritage, reproductive history, body size, and smoking. Am J Epidemiol: 2001; 153 1 1 10 (Pubitemid 32041890)
108. D'Aloisio A. A., Baird D. D., DeRoo L. A., Sandler D. P. Early-life exposures and early-onset uterine leiomyomata in black women in the Sister Study. Environ Health Perspect: 2012; 120 3 406 412
109. Wegman H. L., Stetler C. A meta-analytic review of the effects of childhood abuse on medical outcomes in adulthood. Psychosom Med: 2009; 71 8 805 812
110. Felitti V. J., Anda R. F., Nordenberg D., et al. Relationship of childhood abuse and household dysfunction to many of the leading causes of death in adults. The Adverse Childhood Experiences (ACE) Study. Am J Prev Med: 1998; 14 4 245 258
111. Goodwin R. D., Stein M. B. Association between childhood trauma and physical disorders among adults in the United States. Psychol Med: 2004; 34 3 509 520 (Pubitemid 38559152)
112. Boynton-Jarrett R., Rich-Edwards J. W., Jun H. J., Hibert E. N., Wright R. J. Abuse in childhood and risk of uterine leiomyoma: the role of emotional support in biologic resilience. Epidemiology: 2011; 22 1 6 14
113. Baird D., Wise L. A. Childhood abuse and fibroids. Epidemiology: 2011; 22 1 15 17
114. Kant A. K., Graubard B. I. Ethnicity is an independent correlate of biomarkers of micronutrient intake and status in American adults. J Nutr: 2007; 137 11 2456 2463 (Pubitemid 350058716)
115. Timbo B. B., Ross M. P., McCarthy P. V., Lin C. T. Dietary supplements in a national survey: prevalence of use and reports of adverse events. J Am Diet Assoc: 2006; 106 12 1966 1974 (Pubitemid 44779443)
116. Rock C. L. Multivitamin-multimineral supplements: who uses them? Am J Clin Nutr: 2007; 85 1 277S 279S (Pubitemid 46067648)
117. Wise L. A., Radin R. G., Palmer J. R., Kumanyika S. K., Boggs D. A., Rosenberg L. Intake of fruit, vegetables, and carotenoids in relation to risk of uterine leiomyomata. Am J Clin Nutr: 2011; 94 6 1620 1631
118. Wise L. A., Palmer J. R., Harlow B. L., et al. Risk of uterine leiomyomata in relation to tobacco, alcohol and caffeine consumption in the Black Women's Health Study. Hum Reprod: 2004; 19 8 1746 1754 (Pubitemid 39144616)
119. Wickett R. R. Permanent waving and straightening of hair. Cutis: 1987; 39 6 496 497 (Pubitemid 17089141)
120. Hauser R., Calafat A. M. Phthalates and human health. Occup Environ Med: 2005; 62 11 806 818 (Pubitemid 41565017)
121. Weuve J., Hauser R., Calafat A. M., Missmer S. A., Wise L. A. Association of exposure to phthalates with endometriosis and uterine leiomyomata: findings from NHANES, 1999-2004. Environ Health Perspect: 2010; 118 6 825 832
122. Huang P. C., Tsai E. M., Li W. F., et al. Association between phthalate exposure and glutathione S-transferase M1 polymorphism in adenomyosis, leiomyoma and endometriosis. Hum Reprod: 2010; 25 4 986 994
123. Wise L. A., Palmer J. R., Reich D., Cozier Y. C., Rosenberg L. Hair relaxer use and risk of uterine leiomyomata in African-American women. Am J Epidemiol: 2012; 175 5 432 440
124. Thoits P. A. Stress, coping, and social support processes: where are we? What next? J Health Soc Behav: 1995; (Spec No): 53 79
125. Nepomnaschy P. A., Welch K., McConnell D., Strassmann B. I., England B. G. Stress and female reproductive function: a study of daily variations in cortisol, gonadotrophins, and gonadal steroids in a rural Mayan population. Am J Hum Biol: 2004; 16 5 523 532 (Pubitemid 39199846)
126. Vines A. I., Ta M., Esserman D., Baird D. D. A comparison of the occurrence and perceived stress of major life events in black and white women. Women Health: 2009; 49 5 368 380
127. Williams D. R., Mohammed S. A. Discrimination and racial disparities in health: evidence and needed research. J Behav Med: 2009; 32 1 20 47
128. Vines A. I., Ta M., Esserman D. A. The association between self-reported major life events and the presence of uterine fibroids. Womens Health Issues: 2010; 20 4 294 298